Last month, an experimental pancreatic cancer drug from Infinity Pharmaceuticals (INFI) failed a mid-stage study because patients were not living longer. Clovis Oncology (CLVS) and Celgene (CELG) are each, separately, conducting studies of pancreatic cancer drugs with results expected later this year.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein.
>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.
>To submit a news tip, send an email to: firstname.lastname@example.org.Follow TheStreet on Twitter and become a fan on Facebook.